Pemetrexed Plus Oxaliplatin as Adjuvant Chemotherapy for Radically Resected Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this phase II trial is to evaluate the clinical feasibility-in terms of
patients without dose limiting toxicities or premature treatment withdrawal or death-of
administering adjuvant chemotherapy of pemetrexed followed by pemetrexed/oxaliplatin
immediately post-video-assisted thoracic surgery (VATS) in patients with completely resected
Non-Small Cell Lung Cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University